Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donya Moradi Manesh

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Blood|June 28, 2015
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemiaDonya Moradi Manesh, Jad El-Hoss, Kathryn Evans, et al.
Pediatric Blood & Cancer|September 17, 2013
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing ProgramHernan Carol, Richard Gorlick, E Anders Kolb, et al.
Biochemical Pharmacology|January 18, 2014
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cellsStephen M F Jamieson, Yongchuan Gu, Donya Moradi Manesh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2014
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsSanti Suryani, Hernan Carol, Triona Ni Chonghaile, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Blood|June 28, 2015
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemiaDonya Moradi Manesh, Jad El-Hoss, Kathryn Evans, et al.
Pediatric Blood & Cancer|September 17, 2013
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing ProgramHernan Carol, Richard Gorlick, E Anders Kolb, et al.
Biochemical Pharmacology|January 18, 2014
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cellsStephen M F Jamieson, Yongchuan Gu, Donya Moradi Manesh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2014
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsSanti Suryani, Hernan Carol, Triona Ni Chonghaile, et al.
Pageof 1